Acrux 과거 수익 실적
과거 기준 확인 0/6
Acrux has been growing earnings at an average annual rate of 22.4%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 57.9% per year.
주요 정보
22.4%
수익 성장률
34.0%
EPS 성장률
Pharmaceuticals 산업 성장 | 31.2% |
매출 성장률 | 57.9% |
자기자본 수익률 | -177.0% |
순이익 | -113.9% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet
Nov 16It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year
Nov 16We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully
Sep 21Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation
May 20Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?
Feb 04Here's What We Think About Acrux's (ASX:ACR) CEO Pay
Dec 14수익 및 비용 분석
Acrux 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 5 | -6 | 6 | 0 |
31 Mar 24 | 8 | -3 | 6 | 0 |
31 Dec 23 | 11 | -1 | 6 | 0 |
30 Sep 23 | 10 | -1 | 6 | 0 |
30 Jun 23 | 8 | -1 | 6 | 0 |
31 Mar 23 | 5 | -4 | 6 | 0 |
31 Dec 22 | 2 | -8 | 6 | 0 |
30 Sep 22 | 2 | -9 | 6 | 0 |
30 Jun 22 | 2 | -10 | 7 | 0 |
31 Mar 22 | 1 | -10 | 7 | 0 |
31 Dec 21 | 1 | -10 | 7 | 0 |
30 Sep 21 | 1 | -11 | 7 | 0 |
30 Jun 21 | 1 | -13 | 7 | 0 |
31 Mar 21 | 1 | -12 | 7 | -1 |
31 Dec 20 | 2 | -11 | 7 | -2 |
30 Sep 20 | 1 | -10 | 6 | -1 |
30 Jun 20 | 1 | -9 | 6 | 0 |
31 Mar 20 | 0 | -10 | 6 | 1 |
31 Dec 19 | -1 | -11 | 7 | 2 |
30 Sep 19 | 0 | -10 | 7 | 1 |
30 Jun 19 | 1 | -8 | 7 | 0 |
31 Mar 19 | 2 | -9 | 7 | 0 |
31 Dec 18 | 3 | -9 | 7 | 0 |
30 Sep 18 | 3 | -12 | 8 | 0 |
30 Jun 18 | 3 | -14 | 8 | 0 |
31 Mar 18 | 8 | -15 | 8 | 0 |
31 Dec 17 | 12 | -15 | 9 | 0 |
30 Sep 17 | 18 | -8 | 8 | 0 |
30 Jun 17 | 24 | 0 | 7 | 0 |
31 Mar 17 | 24 | 5 | 7 | 0 |
31 Dec 16 | 25 | 10 | 6 | 0 |
30 Sep 16 | 27 | 11 | 6 | 0 |
30 Jun 16 | 29 | 13 | 5 | 0 |
31 Mar 16 | 29 | 13 | 5 | 0 |
31 Dec 15 | 29 | 14 | 5 | 0 |
30 Sep 15 | 27 | 12 | 5 | 0 |
30 Jun 15 | 25 | 11 | 5 | 0 |
31 Mar 15 | 25 | 11 | 4 | 0 |
31 Dec 14 | 24 | 10 | 4 | 0 |
30 Sep 14 | 39 | 19 | 4 | 0 |
30 Jun 14 | 54 | 28 | 4 | 0 |
31 Mar 14 | 55 | 29 | 4 | 0 |
31 Dec 13 | 55 | 30 | 4 | 0 |
양질의 수익: ACR is currently unprofitable.
이익 마진 증가: ACR is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: ACR is unprofitable, but has reduced losses over the past 5 years at a rate of 22.4% per year.
성장 가속화: Unable to compare ACR's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: ACR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
자기자본 수익률
높은 ROE: ACR has a negative Return on Equity (-177.05%), as it is currently unprofitable.